Patients with sarcomatoid renal cell carcinoma – re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors

Roberto Iacovelli, Chiara Ciccarese, Emilio Bria, Sergio Bracarda, Camillo Porta, Giuseppe Procopio, Giampaolo Tortora

Risultato della ricerca: Contributo in rivistaArticolo in rivista

Abstract

Materials and methods: For this meta-analysis, we searched MEDLINE/PubMed, the Cochrane Library and American Society of Medical Oncology (ASCO) Meeting abstracts for phase II or III randomised clinical trials. Data extraction was conducted according to the Preferred Reporting Items for Systematic Review and Meta-Analysis statement. The hazard ratios (HRs) for progression-free survival (PFS) and overall survival (OS) with the relative 95% confidence intervals were extracted from studies. Summary HRs were calculated using random- or fixed-effects models, depending on the heterogeneity of the included studies. Results: Four studies were selected for final analysis, including 467 patients (226 treated in with ICI combinations and 241 received sunitinib in the control arms). ICI-based combinations were associated with an improved PFS and OS compared with sunitinib, with a reduction of more than 40% of progression (HR = 0.56; p < 0.0001) and mortality (HR = 0.56; p = 0.001) risk. Moreover, ICI-based combinations are associated with a objective response rate (ORR) of more than 50% (versus 20% with sunitinib), corresponding to a doubled risk of achieving an ORR compared with controls (relative risk [RR] = 2.15; p < 0.00001). Finally, immunotherapy significantly increased the possibility to obtain complete responses (RR = 8.15, p = 0.0002) with an incidence of 11%. Conclusion: Our data support the efficacy of ICI-based combinations for sRCC therapy, redefining the first-line treatment. Keywords: Immune checkpoint inhibitor combinations; Immunotherapy; Renal cell carcinoma; Sarcomatoid RCC.
Lingua originaleEnglish
pagine (da-a)195-203
Numero di pagine9
RivistaEuropean Journal of Cancer
Volume136
DOI
Stato di pubblicazionePubblicato - 2020

Keywords

  • Renal cell carcinoma

Fingerprint

Entra nei temi di ricerca di 'Patients with sarcomatoid renal cell carcinoma – re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors'. Insieme formano una fingerprint unica.

Cita questo